Gregory Bojrab
Internal Medicine · New Castle, INNPI 1922090182
Payments from drug & device makers
Across 344 payments — averaging $35.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$1K
- Lilly USA, LLC$995
- AbbVie$961
- E.r. Squibb & Sons, L.L.C.$934
- GSK$741
- plus $4K from 29 others
What the payments were for
- Food & beverage$12,247100%
- Education$460%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 46 | $3,479 |
| Novo Nordisk | 47 | $1,390 |
| Lilly USA, LLC | 42 | $995 |
| AbbVie(2 entities) | 46 | $961 |
| E.r. Squibb & Sons, L.L.C. | 17 | $934 |
| GSK | 28 | $741 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $558 |
| Teva Pharmaceuticals USA, Inc. | 4 | $369 |
| Biohaven Pharmaceuticals, Inc. | 3 | $359 |
| Amgen | 10 | $316 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $265 |
| Medtronic | 5 | $234 |
| Pfizer | 12 | $232 |
| Exact Sciences | 5 | $174 |
| Alnylam Pharmaceuticals Inc. | 4 | $167 |
| Johnson & Johnson | 5 | $138 |
| Amarin Pharma, Inc. | 2 | $120 |
| Bayer | 6 | $113 |
| Phathom Pharmaceuticals, Inc. | 4 | $110 |
| Sanofi Pasteur Inc. | 2 | $108 |
| Novartis | 5 | $77 |
| Lundbeck LLC | 4 | $62 |
| Axsome Therapeutics, Inc. | 4 | $60 |
| Boehringer Ingelheim | 3 | $54 |
| Corium, LLC | 4 | $45 |
| Otsuka America Pharmaceutical, Inc. | 3 | $43 |
| Biogen | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Axonics, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Merck | 1 | $13 |
| Covis Pharma GmbH | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,293 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 32 | $29,718 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $21,622 |
| FarxigaDapagliflozin Propanediol | 24 | $15,530 |
| EliquisApixaban | 17 | $13,507 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $9,817 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,060 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,855 |
| Ventolin HfaAlbuterol Sulfate | 17 | $949 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 60 | $900 |
| Gabapentin | 52 | $822 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $710 |
| Omeprazole | 44 | $530 |
| Valsartan | 13 | $347 |
| Celecoxib | 24 | $342 |
| Chlorthalidone | 11 | $301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $741 | $31,43955 claims |
| Novo NordiskOzempic | $1,390 | $29,71832 claims |
| AstraZenecaFarxiga | $3,479 | $15,53024 claims |
| PfizerEliquis | $232 | $13,50717 claims |
| Boehringer IngelheimSpiriva Respimat | $54 | $6,06012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in New Castle
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.